Advancing Affordable Medicines for Families Act

Bill: 117-s-4341
Sponsor: full_name: Sen. Rosen, Jacky [D-NV]
Introduced: 2022-05-26
Policy area: Health
Latest action: action_date: 2022-05-26
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summaries:
action_date: 2022-05-26
action_desc: Introduced in Senate
text: <p><strong>Advancing Affordable Medicines for Families Act</strong></p> <p>This bill requires the Government Accountability Office to report on the potential impact of nonprofit pharmaceutical organizations on the availability and cost of drugs as well as such organizations' potential to accelerate development of new drugs, generic drugs, new biological products, biosimilar products, cell-based therapies, and medical devices.</p>

tv_txt: II 117th CONGRESS 2d Session S. 4341 IN THE SENATE OF THE UNITED STATES May 26, 2022 Ms. Rosen (for herself and Mr. Romney ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To require the Government Accountability Office to issue a report on nonprofit pharmaceutical organizations.

1. Short title This Act may be cited as the Advancing Affordable Medicines for Families Act . 2. GAO report on nonprofit pharmaceutical organizations The Comptroller General of the United States shall submit a report to Congress on the following: (1) The potential impact of nonprofit pharmaceutical organizations on the availability and cost of drugs, including on drug shortages, consumer costs, and costs to Federal programs. (2) The potential of nonprofit pharmaceutical organizations to accelerate development of new drugs, generic drugs, new biological products, biosimilar biological products, cell-based therapies, and devices. (3) Existing barriers to the success of nonprofit pharmaceutical organizations, including the ability of such organizations to obtain tax-exempt status, access to capital, and access to markets. (4) Potential actions by Congress that would allow nonprofit pharmaceutical organizations to deliver benefits to the pharmaceutical market.